Clinical Trial

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

Study acronym: MIND
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Trial Details
NCT Number NCT07282470
Lead Sponsor Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Collaborators: University of Milan, Università degli Studi del Piemonte Orientale Amedeo Avogadro
Conditions Meningioma, Meningioma of Brain
Enrollment 210 participants
Start Date 2024-09-25
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-10